United States Patent 12,605,365 Landscape: Scope of Claims Covering Oral Losartan Liquid Suspensions for Hypertension and Nephropathy
US Patent 12,605,365 is directed to method-of-treatment claims that rely on a specific oral liquid formulation definition: a losartan (or salt, including losartan potassium) liquid suspension at about 10 mg/mL, with a defined suspending-agent genus, a pH of about 7, and specified excipient classes (pH modifying agent, preservative, solubilizer), with dependent claim refinements that narrow preservative type (parabens), pH salts (sodium phosphate monobasic/dibasic), and selected optional components (PEG 400, propylene glycol, crystallization inhibitor, anti-foaming agent, mint flavor, xanthan gum as suspending agent).
The practical patent “scope” is therefore not just “losartan for hypertension/nephropathy,” but “loss-controlled infringement” through a formulation-and-route-dependent treatment method claim.
What does US Patent 12,605,365 claim protect: oral losartan liquid suspension methods for hypertension and nephropathy?
Core independent claim structure (Claims 1 and 11)
Both independent claims are formulation-defined method-of-use claims with the same backbone:
- Treatment method:
- Claim 1: treating hypertension
- Claim 11: treating nephropathy
- Administration to a human in need thereof of an oral pharmaceutical composition that is:
- A liquid suspension
- Contains about 10 mg/mL losartan or a pharmaceutically acceptable salt
- Has suspending agent chosen from a defined list (genus)
- Contains:
- pH modifying agent
- preservative
- solubilizer
- Has liquid suspension pH of about 7
Implication for scope: A product that is a solid tablet/capsule losartan is outside claim scope unless it is “liquid suspension” as claimed. A liquid suspension with a pH materially different from about 7, or without the specified component classes (or without an equivalent suspending agent/pH system/solubilizer/preservative), is outside the claim as written.
Combination indication independent claim (Claim 20)
- Claim 20: treating hypertension or diabetic nephropathy
- Requires the same suspension construct plus explicit inclusion of:
- emulsifying agent
- crystallization inhibitor
- Maintains:
- about 10 mg/mL losartan potassium
- suspending agent genus
- pH about 7
- preservative and solubilizer
- plus the defined emulsifying/crystallization elements
Implication for scope: Claim 20 is narrower than claims 1/11 because it requires extra excipient classes (emulsifying agent and crystallization inhibitor).
How are the excipient and pH limitations drafted: what exact formulation elements control infringement risk?
Suspending agent genus limitation
Independent claims require suspending agent selected from:
- hydroxyethylcellulose
- methylcellulose
- hydroxymethylcellulose
- hydroxypropylmethylcellulose
- microcrystalline cellulose
- sodium carboxymethylcellulose
- xanthan gum
- acacia
- an alginate
- guar gum
(or combinations)
Infringement effect: The claim is broad on the suspending-agent choice, but still anchored to the listed genera. If a competitor uses a different suspending system (for example, different polymer not captured by the enumerated list) it may avoid literal infringement unless doctrine-of-equivalents arguments succeed.
“pH modifying agent” limitation (with narrowing dependent claims)
- Independent: requires a pH modifying agent
- Dependent claim examples:
- Claim 7/17: pH modifying agent comprises sodium phosphate monobasic and/or sodium phosphate dibasic
Infringement effect: The independent claims keep pH system broad at the “pH modifying agent” class level, but dependent claims narrow to phosphate salts. A competitor using a different buffer system could still infringe claim 1/11 if it has a pH modifying agent and the final suspension pH is about 7.
Preservative and dependent narrowing
- Independent: requires a preservative
- Dependent:
- Claim 6/16: preservative comprises methyl paraben and/or propyl paraben
Infringement effect: Independent claims are not limited to parabens. A competitor using different preservatives could still fall within claim 1/11 if it uses “a preservative” meeting the claim term and maintains pH about 7 and the other required components.
Solubilizer requirement
- Independent: requires a solubilizer
- No specific solubilizer list appears in the provided claim text.
Infringement effect: The solubilizer term is a key formulation handle. Competitive liquid suspensions that do not include a solubilizer strategy for losartan may attempt to argue non-inclusion.
pH limitation: “about 7”
- Independent claims set final composition pH to about 7
Infringement effect: This is likely the highest-yield design-around parameter. Even if other excipient elements are matched, deviating the final suspension pH away from “about 7” can move the product outside claim scope. Whether the deviation remains inside “about” is a claim construction issue, but the formulation barrier is real.
What dependent claim details expand or narrow coverage: parabens, PEG 400, crystallization inhibitors, and anti-foaming agents?
Optional excipient classes that still define infringement if present
Dependent claims incorporate optional elements on top of claims 1/11, meaning infringement can occur if the accused composition practices the dependent feature set in addition to the independent claim baseline.
- Claim 2/12: further comprises one or more excipients from:
- emulsifying agent, antioxidant, chelating agent, surfactant/wetting agent, sweetener, stabilizer, flavoring agent, colorant
- Claim 3/18: further comprises crystallization inhibitor
- Claim 5/15: further comprises PEG 400, propylene glycol, or both
- Claim 6/16: preservative comprises methyl paraben and/or propyl paraben
- Claim 7/17: pH modifying agent comprises sodium phosphate monobasic and/or dibasic
- Claim 8: flavoring agent comprises mint flavor
- Claim 9/13: suspending agent comprises xanthan gum
- Claim 10/19: further comprises anti-foaming agent
- Claim 4/14: salt is losartan potassium
Where claim 20 narrows beyond dependent coverage
Claim 20 explicitly requires:
- losartan potassium
- emulsifying agent
- crystallization inhibitor
plus the baseline suspension parameters including pH about 7
This gives a specific target product profile, likely aligned to an intended commercial formulation.
How broad is the claim “genus” vs “specific substance” coverage?
Broadest elements
- Suspending-agent genus (10 enumerated candidates)
- Presence of a pH modifying agent, preservative, and solubilizer (not limited to a specific chemical list in the independent claims)
- Indication-level breadth across hypertension and nephropathy (and diabetic nephropathy in claim 20)
Narrowest elements
- Liquid suspension requirement
- About 10 mg/mL concentration
- pH about 7
- Treatment indications tethered to the defined formulation for method-of-use infringement
What patents protect losartan formulations with pH ~7 and suspending-agent genera: how would this claim map to a likely patent family strategy?
No other US patent numbers, assignees, priority claims, or expiration dates were provided with the prompt. Without those, the full “landscape” cannot be completed in an evidence-backed way. What can be concluded from claim drafting strategy alone is:
- This is a formulation-driven method-of-use claim (not a composition-for-sale claim). That often indicates the innovator is protecting a commercial liquid suspension presentation where standard losartan exists as tablets/capsules but the claimed competitive gap is the liquid.
- The excipient genus suggests the patentee expected manufacturing variability (substitution among commonly accepted suspension polymers) while keeping a single infringement “net.”
- The pH of about 7 suggests the patentee identified a stability, solubility, or suspension-shear window that avoids precipitation or sedimentation.
- Crystallization inhibitor and anti-foaming agent appear in dependent claims. Those are typical flags for physical stability and manufacturing reproducibility, suggesting the claimed formulation was tuned for long-term suspension uniformity.
When does US 12,605,365 lose exclusivity: what is the expected expiration and how do patent term adjustments affect it?
No filing date, priority date, PTA, patent term extension, or terminal disclaimer details were provided. A definitive timeline and loss-of-exclusivity date cannot be calculated from the prompt alone.
What generic entry risks exist for losartan oral liquid suspensions: where could design-arounds avoid claim scope?
High-leverage design-around levers
- Shift pH away from “about 7.”
If the final suspension pH is moved sufficiently, claims 1/11/20 may be avoided even if other components are matched.
- Avoid the “liquid suspension” characterization.
A product characterized as a different dosage form class (for example, a different dispersion system not meeting “liquid suspension” as construed) could reduce exposure.
- Change the effective concentration away from about 10 mg/mL.
If the accused product targets a different strength and avoids being “about 10 mg/mL,” literal scope is reduced.
- Reformulate suspending agent outside the enumerated genus.
Use of a non-enumerated suspending system can reduce literal infringement odds, depending on claim construction and equivalents.
- Remove “solubilizer” or “preservative” functions.
Even without listing specific chemicals, the independent claim requires the presence of those functional categories. A competitor may attempt to show its formulation lacks those elements as claimed.
Lower-leverage levers (often covered by genus or dependent claims)
- Using different antioxidants, sweeteners, colors, etc. may not avoid independent claim 1/11 because claim 1/11 already requires only broad classes (preservative/pH modifier/solubilizer/suspending agent).
- Replacing parabens alone may not avoid independent claims because preservatives are not limited to parabens unless dependent claims are asserted.
What patent litigation affects this asset: is it tied to Paragraph IV or settlement risk for generics?
No litigation docket, Hatch-Waxman settlement, Paragraph IV notice, or FDA Orange Book entry details were provided with the prompt. A case-specific assessment cannot be produced from the available information.
What is the Orange Book status of US 12,605,365 and how does it constrain FDA generic approvals?
No FDA NDA/ANDA identifiers, Orange Book listing records, or formulation-specific listing status were provided. A status mapping cannot be executed.
How strong is the patent estate for this claim type: are claims likely to be asserted broadly or narrowly?
Based on claim text alone:
- The independent claims (1 and 11) are likely the central enforcement hooks because they capture the core formulation parameters.
- Dependent claims add “extra” features that may support fallback positions if pH, concentration, or formulation composition is disputed.
- Claim 20 provides a narrower combination-indication enforcement angle with extra excipient requirements.
The overall strength hinges on claim construction outcomes for:
- “liquid suspension”
- “about 10 mg/mL”
- “pH of about 7”
- whether the accused formulation contains the required functional categories (pH modifying agent, preservative, solubilizer)
Key Takeaways
- US Patent 12,605,365 protects method-of-treating hypertension/nephropathy using an oral losartan liquid suspension.
- The infringement trigger is tightly tied to formulation definitions: ~10 mg/mL losartan (or losartan potassium), liquid suspension, required suspending-agent genus, pH modifying agent, preservative, solubilizer, and final suspension pH ~7.
- Dependent claims narrow to common commercial formulation variables: parabens, phosphate buffer salts, PEG 400/propylene glycol, crystallization inhibitor, anti-foaming agent, and flavoring/specific suspending agent (xanthan gum).
- The clearest design-around is modifying final pH and/or effective concentration and/or the functional presence of the required formulation elements.
FAQs
- What element in US 12,605,365 is most relevant for design-around pH control in losartan suspensions?
- Can a losartan tablet or capsule avoid infringement if it treats hypertension but is not a liquid suspension?
- Do parabens have to be present to infringe independent claims 1 and 11?
- How do crystallization inhibitors affect infringement when only some excipients match the claim set?
- Is losartan potassium specifically required in all claims or only in certain dependent/combination claims?
References
- US Patent 12,605,365, claim set provided in prompt.
